drugset / Trial / NCT06715124
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Timeline
- Start
- 2025-01-14
- Primary completion
- 2027-01-02
- Completion
- 2029-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | QTX3544 | Unknown | — | — |
Indications
No indication recorded.